Novo Nordisk Sues Eli Lilly Over Zepbound and Mounjaro Advertising

Novo alleges that Lilly relies on outdated studies comparing Lilly’s highest injectable doses with lower doses of Novo medicines while omitting newer, higher-dose Novo options.

What Novo alleges

According to Novo Nordisk, the challenged campaigns compare the maximum tolerated 10 mg and 15 mg doses of Zepbound with 1.7 mg and 2.4 mg Wegovy, without including the FDA-approved 7.2 mg Wegovy dose. Novo makes a parallel allegation about advertisements comparing 15 mg Mounjaro with 1 mg Ozempic while omitting the approved 2 mg Ozempic dose. Those are Novo’s allegations, not findings by the court.

The products at issue span both the obesity and type 2 diabetes markets. Zepbound and Mounjaro are Lilly's dual GIP/GLP-1 receptor agonists, while Wegovy and Ozempic are Novo's GLP-1 receptor agonists. Novo's core allegation is that Lilly's comparative claims are not supported in the manner presented and amount to false advertising under federal law.

The dose-comparison dispute

The dispute is about which studies and approved doses a fair advertising comparison must include. Novo also says there is no head-to-head trial comparing the highest doses of Zepbound and Wegovy. Lilly told Axios that it stands behind its advertising and will defend the lawsuit vigorously.

These allegations are unproven. The lawsuit is a legal action, not a regulatory finding or a scientific determination. Novo's complaint frames the advertising as misleading, but whether the comparisons violate false-advertising standards will be adjudicated in court.

Relief requested

Novo is seeking injunctive relief to stop the disputed advertising, along with monetary damages and other remedies available under false-advertising law. The company has not publicly specified a damages figure but is asking the court to halt the marketing claims it identifies as problematic.

Lilly's response

Eli Lilly says it stands behind its advertising and will defend the lawsuit. The company has pushed back against the premise of Novo's allegations, setting up a contested legal proceeding rather than a settlement discussion at this stage.

Why this matters

The lawsuit underscores how high the stakes have become in the GLP-1 market. Direct-to-consumer and provider-facing advertising for these drugs has grown substantially, and comparative claims are a flashpoint because they can influence prescribing decisions and consumer demand. False-advertising litigation between major pharmaceutical manufacturers is one mechanism through which marketing boundaries get tested, but it is a slow one. A court resolution could take considerable time, and the outcome is not predictable from the complaint alone.

Material limitations

• The allegations are disputed and unproven. This article does not assess the merits of either party's claims.
• No regulatory authority has ruled that Lilly's advertising is false or misleading.
• The lawsuit addresses advertising claims, not the underlying safety or efficacy profiles of the drugs themselves.
• This article does not provide medical advice or dosing guidance. Patients should consult qualified healthcare professionals regarding any medication.

What to watch

The key developments will be whether the court grants any preliminary injunctive relief, how Lilly responds in its formal answer to the complaint, and whether any documents emerge during discovery that clarify the basis of the dose-comparison claims. Until then, the dispute remains allegations and denials.